Impact of Smoking Cessation on Sleep - 5

Sponsor

National Institute on Drug Abuse (NIDA) (NIH)

Overall Status

Completed

CT.gov ID

NCT00132821

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

1.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Smoking is a major health problem with a direct link to elevated heart- and lung-related problems. Nicotine is highly addictive, which makes quitting difficult and relapse after quitting highly probable. Any type of sleep disturbance may make quitting even harder. The purpose of this study is to evaluate the effect of bupropion and nicotine replacement therapies (NRT) on sleep disturbances. In turn, this might show how such medications affect attempts at smoking cessation.

Condition or Disease	Intervention/Treatment	Phase
Tobacco Use Cessation Sleep Disorders	Drug: Bupropion Drug: Transdermal Nicotine Patch Drug: Placebo Bupropion Drug: Placebo transdermal nicotine patch	Phase 4

Detailed Description

The majority of attempts to quit smoking end in failure due to unpleasant withdrawal symptoms. One such symptom is sleep disturbances. Bupropion, effective in assisting with smoking cessation, commonly causes sleep disturbances as a medication side effect. In addition, a number of NRTs also cause sleep disturbances. This study will aim to characterize the effect of smoking cessation and smoking cessation treatments on sleep by measuring central and autonomic nervous system arousal. The study will also evaluate the impact of smoking cessation treatments on daytime sleepiness and mood as well as their effect on smoking relapse.

Participants will be randomly assigned to one of four groups. Participants will receive either bupropion (150 mg for 3 days and 300 mg for 60 days) or placebo, starting one week prior to smoking quit day. They will then receive either active NRT (21 mg for 6 weeks, 14 mg for 1 week, and 7 mg for 1 week) or placebo, starting on quit day. Participants will be studied for up to 5 nights in a sleep lab. Sleep studies will include polysomnography measurements, including electrooculography of both eyes, activity of mentalis muscle and both anterior tibialis muscles, EEG, ECG, oxygen saturation, airflow, and respiratory efforts. Sleep studies will occur on the 2 nights prior to quit day, the quit night, and the 2 nights after quitting. Each sleep study will be followed by daytime measures. These will include a series of self-report instruments, sleepiness and performance measures, and physiological activity measures. Carbon monoxide levels will also be a daytime measurement and must fall below 10 ppm on the post quit days. All participants will receive bimonthly phone counseling for 12 months, starting on quit day. Participants will have follow-up evaluations at Months 3 and 12 in order to measure carbon monoxide levels and complete self-report instruments.

Study Design

Study Type:

Interventional

Actual Enrollment :

59 participants

Allocation:

Randomized

Intervention Model:

Factorial Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Impact of Smoking Cessation on Sleep

Study Start Date :

Aug 1, 2005

Actual Primary Completion Date :

May 1, 2009

Actual Study Completion Date :

May 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: A Bupropion	Drug: Bupropion Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm) Other Names: Zyban
Active Comparator: B Transdermal nicotine patch	Drug: Transdermal Nicotine Patch 21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
Placebo Comparator: C	Drug: Placebo Bupropion Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
Placebo Comparator: D	Drug: Placebo transdermal nicotine patch 21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week

Outcome Measures

Primary Outcome Measures

Pre- and post-cessation sleep measures by in-laboratory polysomnography [Up to 7 days post-cessation]

Secondary Outcome Measures

Smoking cessation status confirmed by carbon monoxide levels [Up to 12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Meets DSM-IV criteria for nicotine dependence
History of smoking at least 20 cigarettes each day for 2 years prior to enrollment
Expired carbon monoxide level of at least 10 ppm
Body mass index less than 30 kg/m2

Exclusion Criteria:

Meets DSM-IV criteria for dependence on substances other than nicotine and caffeine
Substance abuse within the year prior to enrollment
History of DSM-IV diagnosis of schizophrenia, bipolar disorder, obsessive compulsive disorder, or chronic depression
Current diagnosis of major depression
History of neurological illness or trauma (e.g., stroke, seizure disorder, febrile seizures, electroconvulsive therapy)
Family history of seizure disorder
History of head injury with loss of consciousness for longer than 1 hour
Currently diagnosed with a sleep disorder
Currently diagnosed with anorexia or bulimia
Severe or chronic cardiovascular, lung, kidney, or neurological disease
Uncontrolled hypertension or diabetes
Use of medications contraindicated with bupropion
High frequency alcohol use or binge drinking in the month prior to enrollment
Pregnant or breastfeeding